引用文本：饶佳伟, 许诗语, 陈创奇. 2024年度结直肠癌治疗研究进展[J/CD]. 消化肿瘤杂志（电子版）, 2025, 17(2):182-188.

作者：饶佳伟，许诗语，陈创奇

单位：中山大学附属第一医院 胃肠外科中心，广东 广州 510080

Authors：Rao Jiawei, Xu Shiyu, Chen Chuang

Unit：Gastrointestinal Surgery Department, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China

摘要：

结直肠癌是全球范围内最常见的恶性肿瘤之一。在我国，结直肠癌的发病率和死亡率位居所有恶性肿瘤中的第2位和第5位，严重危害国民健康。随着手术技术、药物研发、治疗理念等多方面的发展，2024年结直肠癌的诊治取得了长足的进步，各种临床研究不断涌现，提供了充足的循证医学证据。其中，免疫治疗已成为研究热点，在微卫星不稳定与微卫星稳定结直肠癌中，关于免疫单药治疗、双重免疫治疗、化疗免疫治疗联合等治疗组合的探索日渐增多。较高的病理完全缓解率也给结直肠癌患者的器官保留带来希望。总体而言，结直肠癌治疗向着多学科诊疗、微创化、器官保留化的方向发展。本文旨在回顾2024年度结直肠癌治疗的研究进展，为后续研究提供新思路。

关键词：结直肠癌；加速康复外科；器官保留；免疫治疗

Abstract：

Colorectal cancer is one of the most common malignant tumors worldwide. In China, the incidence rate and mortality of colorectal cancer rank the second and fifth among all malignant tumors, seriously endangering national health. With the development of surgical techniques, clinical research, treatment concepts and other aspects, significant progress has been made in the diagnosis and treatment of colorectal cancer in 2024. Various clinical studies continue to emerge, improving evidence-based medicine significantly. Among them, immunotherapy has become a research hotspot. In microsatellite unstable and microsatellite stable colorectal cancer, there is an increasing exploration of treatment combinations such as single immune therapy, dual immune therapy, and chemoimmunotherapy. The higher pathological complete remission rate also brings hope for organ preservation in colorectal cancer patients. Overall, the treatment of colorectal cancer is developing towards multidisciplinary diagnosis and treatment, minimally invasive techniques, and organ preservation. This article aims to review the research progress on the treatment of colorectal cancer in 2024 and provide new ideas for future research.

Key words：Colorectal cancer; Enhanced recovery after surgery; Organ preservation; Immunotherapy

注：网络优先发布